📺 Live now:
Next week: U.S.-China Commission hearing ⬇️ An Axis of Autocracy? China’s Relations with Russia, Iran, and North Korea https://lnkd.in/e27eq9ca
The U.S.-China Economic and Security Review Commission (USCC) was created by the United States Congress on October 30, 2000 by the Floyd D. Spence National Defense Authorization Act for 2001 (codified at 22 U.S.C. §7002) with the legislative mandate to monitor, investigate, and submit to Congress an annual report on the national security implications of the bilateral trade and economic relationship between the United States and the People’s Republic of China, and to provide recommendations, where appropriate, to Congress for legislative and administrative action. In accordance with its mandate, the Commission focuses its work and study on the following eleven areas: proliferation practices, economic transfers, energy and natural resources, foreign investment, military and security affairs, cyber activities, economic conditions, foreign affairs, compliance and enforcement, freedom of information, and product safety. The Commission has 12 members, three of whom are appointed by each of the Majority and Minority Leaders of the Senate, and the Speaker and the Minority Leader of the House. The Commissioners serve two-year terms. The Commissioners are supported by policy and administrative staff with extensive backgrounds in trade, economics, national security, foreign policy, and U.S.-China relations.
U.S.-China Economic and Security Review Commission的外部链接
444 N Capitol St NW
US,District of Columbia,Washington
📺 Live now:
Next week: U.S.-China Commission hearing ⬇️ An Axis of Autocracy? China’s Relations with Russia, Iran, and North Korea https://lnkd.in/e27eq9ca
Next week: U.S.-China Commission hearing ⬇️ An Axis of Autocracy? China’s Relations with Russia, Iran, and North Korea https://lnkd.in/e27eq9ca
U.S.-China Economic and Security Review Commission转发了
Great meeting between the U.S.-China Economic and Security Review Commission and National Security Commission on Emerging Biotechnology (NSCEB). The China Commission recently held a hearing on China's Made in 2025 initiative, where biotech was discussed at length. Learn more 👉 https://lnkd.in/eMxxESBn 🧬 Biology is a strategic domain. It's critical that we act. One of our witnesses emphasized: "we have 1,000 days." One of our top recommendations to the United States Senate and U.S. House of Representatives focused on biotech. See more 👉 https://lnkd.in/e34DCKRE Recent must-read coverage: David Wainer (The Wall Street Journal): "The Drug Industry Is Having Its Own DeepSeek Moment" 👉 https://lnkd.in/eDegKDsV Hannah Kuchler and Wang Xueqiao (Financial Times): "Rapid trials prompt deals rush for Chinese 'super me-too' drugs" 👉 https://lnkd.in/eRz5kyc4 #BiotechSecurity #USChinaTech #GlobalBioInnovation
U.S.-China Economic and Security Review Commission转发了
Big thanks to panelists that joined the U.S.-China Economic and Security Review Commission hearing - “Made in China 2025 - Who is Winning?”. Here are a few great quotes from the day: ✅ "I want to talk about the cost of time⌛. We have less than 1,000 days." ✅ “A whole of nation approach is bigger than civil-military fusion.” ✅ “China is an iterator.” ✅ “Export controls are a depreciating asset.” ✅ “China weaponizes cooperation.” Big thanks to Daniel Blaugher, Matthew Dagher-Margosian, Zoe Merewether, Niels Graham, Benton Gordon, Jameson Cunningham, Christopher Fioravante, and Mike Castellano on the commission staff for all of their work to make the day a success. Great testimony from: ➡️ Richard Aboulafia from AeroDynamic Advisory ➡️ Kyle Chan from Princeton University ➡️ Sunny Cheung from The Jamestown Foundation ➡️ Emily de La Bruyère from Foundation for Defense of Democracies (FDD), ➡️ Hanna Dohmen from Center for Security and Emerging Technology (CSET), ➡️ Drew Endy from Hoover Institution, Stanford University and Freeman Spogli Institute for International Studies, ➡️ David Lin from Special Competitive Studies Project - SCSP, ➡️ Barry Naughton from UC San Diego School of Global Policy and Strategy (GPS), and ➡️ Liza Tobin from Garnaut Global. See more 👉 https://lnkd.in/eMxxESBn Thanks to Commissioner Randy Schriver for co-chairing the hearing with me. And, thanks to Aaron Friedberg, Carte Goodwin, Cliff Sims, Reva Price, Leland Miller, and Hal Brands for joining us. #MadeInChina2025 #USCC #USChina #TechPolicy #Innovation #EmergingTech
🎥 Tune in tomorrow!
Made in China 2025—Who Is Winning? The Commission's first hearing of the year will examine the extent to which China met its Made in China 2025 goals, the tools the United States and partner countries have to respond, and the effectiveness of China's approach to innovation. https://lnkd.in/eR5afxeT
U.S.-China Economic and Security Review Commission转发了
Thanks to Maria Curi at Axios for highlighting the work of the U.S.-China Economic and Security Review Commission's 2024 Annual Report: the creation of a Manhattan Project-style program to develop Artificial General Intelligence (AGI) capabilities. Special thanks to my fellow Commissioner Randy Schriver for joining the conversation and to Jameson Cunningham for his excellent staff work. You can read more of the Commission's work 👉 https://lnkd.in/erqNVxxF
Join the U.S.-China Commission! Two staff positions are currently open on the Security and Foreign Affairs Team: ☑️Policy Analyst/Senior Policy Analyst ☑️Research Assistant https://lnkd.in/eieVjdV
U.S.-China Economic and Security Review Commission转发了
Is China meeting its Made in China 2025 goals? What's the state of play in the US-China technological competition? Next week Randy Schriver and I will co-chair a U.S.-China Economic and Security Review Commission hearing entitled “Made in China 2025—Who Is Winning?” You can learn more 👉 https://lnkd.in/eMxxESBn We've assembled three outstanding panels featuring expert witnesses: Richard Aboulafia, Kyle Chan, Sunny Cheung, Emily de La Bruyère, Hanna Dohmen, Drew Endy, Timothy K., David Lin, Barry Naughton, and Liza Tobin. Looking forward to their insights on everything from aerospace and biotech to AGI to DeepSeek AI and beyond." #MadeInChina2025 #USCC #USChina #TechPolicy #Innovation #EmergingTech
While extremely powerful, AI pales in comparison to the potential of Artificial General Intelligence (AGI). To maintain first-mover advantage in AGI, in November the U.S.-China Commission recommended Congress pursue an effort on the scope and scale of the “Manhattan Project,” with significant, long-term government commitment and public-private collaboration and coordination.
Made in China 2025—Who Is Winning? The Commission's first hearing of the year will examine the extent to which China met its Made in China 2025 goals, the tools the United States and partner countries have to respond, and the effectiveness of China's approach to innovation. https://lnkd.in/eR5afxeT